Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other Countries-Reference-Cited by-同舟云学术

Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other Countries

Published:2019-05 Issue:5 Volume:38 Page:804-811
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Kang So-Yeon¹,DiStefano Michael J.²,Socal Mariana P.³,Anderson Gerard F.⁴

Affiliation:

1. So-Yeon Kang () is a research associate in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, in Baltimore, Maryland.

2. Michael J. DiStefano is a PhD student in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health.

3. Mariana P. Socal is an assistant scientist in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health.

4. Gerard F. Anderson is a professor in the Department of Health Policy and Management and the Department of International Health, Johns Hopkins Bloomberg School of Public Health.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference7 articles.

1. Higher pharmaceutical public expenditure after direct price control: improved access or induced demand? The Colombian case

2. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status

3. The High Cost of Prescription Drugs in the United States

4. Overview of external reference pricing systems in Europe

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis;JAMA Dermatology;2024-04-01

2. Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan;Current Oncology;2023-02-01

3. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019;JAMA Health Forum;2023-01-13

4. Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union;International Journal of Environmental Research and Public Health;2022-09-24

5. International Reference Pricing in the Context of US Drug Policy;Journal of Health Politics, Policy and Law;2022-07-14